Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration

Inclusion Criteria: * Male or female participants between 30 and 75 years of age, diagnosed of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a volume from 10 ml to 60 ml calculated by ABC/2 formula. * Within 5 days from onset to operation, and no improvement. * Glasgow Coma Scale (GCS) score of 9 to 15. * With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength≤grade 3. * Modified Rankin scale (mRS) score≤1 in past medical history. * Women of reproductive age have negative pregnancy tests. * The participants or the legal guardian/representative who are suitable and willing to participate in the clinical trial and can cooperate to complete the follow-ups. Exclusion Criteria: * Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation AVM and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage. * In the sequela stage of cerebral trauma. * Hematoma involves other structures including but not limited to the thalamus and midbrain or complicated with intraventricular hemorrhage. * With neurologic impairment before cerebral hemorrhage onset. * Participants receiving anticoagulant or antiplatelet therapy. * The disease progresses quickly. Manifestation of cerebral herniation such as bilateral dilated pupil, disappearance of light reflex, and unstable vital signs. * Active sta…